ETH-CAT
N-ethylcathinone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
ETH-CAT (N-ethylcathinone) is a synthetic stimulant of the cathinone class. It is the N-ethyl structural analog of cathinone and the primary active metabolite of the appetite suppressant diethylpropion. Ethcathinone is a norepinephrine releaser, producing its effects by flooding the brain's arousal circuits with noradrenaline while weakly blocking dopamine reuptake.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Ethcathinone occurs naturally in Catha edulis (khat)[2] and has been generated in the bodies of patients prescribed diethylpropion since the 1950s,[3] though it was not independently characterized until the 1980s. It first appeared as a marketed recreational substance in 2007 in Australian party pill capsules alongside mephedrone.[4] It is now controlled in most major jurisdictions and encountered only infrequently in forensic casework.
Subjective effects include stimulation, wakefulness, appetite suppression, and cognitive euphoria. The experience emphasizes physical energy and alertness over hedonic reward — a noradrenergic push with secondary serotonergic warmth[5] rather than the dopamine-driven euphoria of more potent cathinones. Compulsive redosing, anxiety, and cardiovascular strain are characteristic unsought effects.
No physical dependence data exist, and no toxic dose has been established in any species. The primary acute risk is cardiovascular — norepinephrine-driven increases in heart rate and blood pressure that scale with dose and compound with polydrug use, the pattern in which ethcathinone is most commonly encountered.[6] No controlled human studies have been conducted; the current understanding rests on a single polysubstance case report, class-level cathinone data, and community experience.
History[edit]
Discovery
Ethcathinone is a naturally occurring alkaloid in Catha edulis (khat)[2] and was first recognized pharmacologically through metabolism studies of diethylpropion, a synthetic appetite suppressant marketed since the 1950s. Beckett and Stanojčić demonstrated in 1987 that mono-N-de-ethylation of diethylpropion — producing ethcathinone — accounts for roughly 35% of the administered dose, confirming it as the principal active species behind diethylpropion's stimulant and anorectic effects.[3] Ethcathinone had thus been continuously produced in the bodies of millions of patients for decades before anyone studied it as a standalone compound.
Recreational emergence
Ethcathinone first surfaced as a recreational product in August 2007, when capsules from an Israel-based internet company were chemically identified in South Australia as containing both N-ethylcathinone and mephedrone — one of the earliest published detections of either compound in consumer products.[4] By 2008 it was marketed in quasi-legal party pills in Australia. Denmark banned ethcathinone in December 2008, and the United Kingdom enacted a blanket cathinone ban in 2010.
Current status
Ethcathinone is now rarely encountered. The UK Advisory Council on the Misuse of Drugs recorded only 20 total detections from 2020–2023, concluding that "further review is not warranted at this stage".[7] Wastewater screening in Slovenian schools confirmed ongoing use in younger populations in 2023,[8] and in 2026 ethcathinone was detected in school-confiscated vapes in the United Kingdom — devices sold as containing THC — representing an uncontrolled exposure route with particular youth relevance.[9]
The name ethcathinone reflects its structure: an N-ethyl substitution on cathinone, the principal stimulant alkaloid of khat. The abbreviation ETH-CAT follows the same naming pattern as METH-CAT (methcathinone). The compound's dual identity — pharmaceutical metabolite and novel psychoactive substance — is unusual: millions of patients have produced ethcathinone internally through prescribed diethylpropion, while the same molecule circulates independently as a controlled recreational drug.
Chemistry[edit]
Structural class
Ethcathinone belongs to the substituted cathinone family, a group of β-keto amphetamine analogs defined by a phenyl ring, an α-amino ketone backbone, and an alkyl side chain. It differs from the parent compound cathinone by the addition of an N-ethyl group, and from methcathinone by one additional carbon on the nitrogen.[10] This single-carbon difference shifts the compound's transporter selectivity away from the purely dopaminergic character of N-methyl analogs toward a more noradrenergic and serotonergic profile.
Ethcathinone is also the active metabolite of diethylpropion (amfepramone), which carries two N-ethyl groups. The liver removes one ethyl group to produce ethcathinone.[3]
Molecular properties
| Molecular formula | C₁₁H₁₅NO |
| Molecular weight | 177.24 g/mol |
The molecule consists of a phenyl ring bonded to a propan-1-one backbone with an ethylamino group at the α-carbon. The β-keto group — the carbonyl adjacent to the phenyl ring — is the defining structural feature that distinguishes cathinones from amphetamines and influences both receptor affinity and metabolic stability.
Stereochemistry
Ethcathinone has one chirality center at the α-carbon, producing R and S enantiomers. X-ray crystallography of the hydrochloride salt confirms that commercially encountered material is racemic mixture.[11] The relative activity of individual enantiomers has not been published; by analogy with cathinone, where the S enantiomer is more potent at monoamine transporters, differential activity is plausible but unconfirmed. inferred
Natural occurrence
Ethcathinone has been identified in dried Catha edulis (khat) material alongside cathinone, methcathinone, and related alkaloids.[2] Whether it is biosynthesized directly by the plant or arises as a degradation product during drying and storage has not been established.
Pharmacology[edit]
Mechanism of action
Ethcathinone acts primarily as a norepinephrine releaser — it forces stored noradrenaline out of nerve terminals through the NET (NET).[1] It also releases serotonin, but unusually for a cathinone, it does not release dopamine. Instead, it weakly blocks the DAT (DAT) without triggering dopamine efflux.[5]
This makes ethcathinone a pharmacological hybrid. Most synthetic cathinones fall into clear categories: dopamine-preferential releasers like methcathinone, mixed releasers like mephedrone, or selective dopamine blockers like MDPV.[12] Ethcathinone fits none of these neatly — its combination of norepinephrine release, serotonin release, and dopamine blockade is atypical within the class.
The N-ethyl group drives this selectivity. Lengthening the N-alkyl chain from one carbon (methcathinone) to two (ethcathinone) shifts the transporter profile away from dopamine dominance toward noradrenergic and serotonergic activity.[10]
Prodrug relationship
Ethcathinone is the primary active metabolite of diethylpropion (amfepramone), a licensed appetite suppressant. Diethylpropion itself has no direct transporter affinity — the liver strips one ethyl group to produce ethcathinone, which accounts for roughly 35% of the administered dose.[3] Only 3–4% of diethylpropion survives unchanged after oral dosing. Sustained-release formulations produce plateau plasma levels of ethcathinone over 6–8 hours.[13]
Pharmacokinetics
No pharmacokinetic data exist for ethcathinone administered directly to humans. All human data derive from studies of its prodrug diethylpropion.
Genetic variation in the liver enzyme CYP3A4 and the transporter protein ABCB1 significantly affects how diethylpropion is metabolized, with four distinct metabolizer types identified in a study of 36 healthy volunteers.[14] This implies substantial person-to-person variability in how much ethcathinone is produced and how quickly it is cleared.
Reported onset (oral: 15–40 minutes), peak (60–90 minutes), and total duration (oral: 3–5 hours) derive from community experience, not published pharmacokinetic studies. safety citation needed Absorption, distribution, protein binding, and clearance for directly administered ethcathinone remain uncharacterized.
Neuroscience[edit]
Where it acts
Ethcathinone's norepinephrine release activates the locus coeruleus arousal system, which projects broadly across the cortex, thalamus, and amygdala.[1] This pathway drives the alertness, wakefulness, and sympathetic nervous system activation that define the experience. Weak dopamine blockade modestly engages the mesolimbic mesolimbic pathway — enough to produce some pleasure, but substantially less than dopamine-releasing cathinones like methcathinone or mephedrone.[12]
Serotonin release from raphe nuclei projections[5] may add a subtle mood-lifting quality and could contribute to the dangerous sodium depletion documented in clinical reports via serotonin-mediated fluid imbalance.[6]
Why it matters
Ethcathinone's pharmacology maps onto the incentive salience framework: noradrenergic arousal drives "wanting" (motivational urgency) while weak dopaminergic activity provides limited "liking" (hedonic reward). This mismatch — high drive with modest payoff — may explain the compulsive redosing pattern users report, where the urge to take more outpaces the satisfaction each dose provides.
Chronic cathinone use produces transporter downregulation and receptor desensitization.[15] Whether ethcathinone preferentially induces tolerance or behavioral sensitization has not been studied.
The magnitude of ethcathinone's serotonin release is unquantified — at what dose does it become clinically significant, and does it contribute to subjective effects or mainly to adverse events like sodium depletion? No data exist on whether chronic use produces neurotoxicity, though synthetic cathinones as a class show neurotoxic potential in animal models.[16] The pharmacological activity of individual enantiomers remains unexplored.
Subjective Effects[edit]
Ethcathinone delivers a stimulant experience built on noradrenergic arousal rather than dopaminergic reward. The result is an energizing, wakeful state with appetite suppression and mild mood elevation — functional alertness more than recreational euphoria. At higher doses the serotonergic component may become more apparent as subtle warmth, though the dominant character remains physical stimulation and restless energy. Set and setting strongly influence whether the noradrenergic push reads as productive focus or anxious agitation.
Compared to mephedrone, ethcathinone is described as less euphoric and less empathogenic, consistent with its weaker dopamine and serotonin activity. Relative to amphetamine, it occupies a lower-potency, shorter-duration position with less sustained attentional utility and a more diffuse, edgy stimulant character.
Effect Grid
Clear stimulant effects emerge — pronounced stimulation, sustained wakefulness, and noticeable appetite suppression. Cognitive euphoria and focus enhancement become apparent. Thought acceleration produces a sense of mental sharpness and increased motivation.
Sympathomimetic activation is more prominent: elevated heart rate, potential bruxism, and mild dehydration sensation. Some tactile euphoria may be present. The compulsive redosing urge may emerge, particularly with insufflated administration where the shorter duration intensifies the drive to re-dose.
Insomnia is likely if taken within 4–5 hours of intended sleep. The overall character is more "functional stimulation" than euphoric rush, reflecting ethcathinone's NET-preferential profile with weak dopaminergic reward.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Visual haze / noise
Pupil dilation · Dry mouth · Insomnia · Physical fatigue · Restlessness · Dehydration sensation · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tactile euphoria · Dizziness · Respiratory stimulation · Trembling · Motor control impairment
Physical fatigue · Restlessness · Dehydration sensation · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tactile euphoria · Dizziness · Respiratory stimulation · Trembling
Focus enhancement · Motivation enhancement · Motivation suppression · Immersion enhancement · Information processing enhancement · Thought organization · Analysis enhancement · Thought deceleration · Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Pattern recognition enhancement · Language enhancement · Memory enhancement · Confusion · Thought disorganization
Information processing enhancement · Thought organization · Analysis enhancement · Thought deceleration · Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Pattern recognition enhancement · Language enhancement · Memory enhancement · Confusion · Thought disorganization
Anhedonia · Dysphoria
Ego inflation · Sociability enhancement · Social connection · Flow state · Depersonalization · Derealization
Depersonalization · Derealization
Timeline
Gradual awareness of stimulant effects emerges — subtle increase in heart rate and alertness. Most users notice a faint shift in baseline arousal before distinct effects manifest.
Stimulation builds steadily. Mood elevation emerges, appetite suppression begins, and noradrenergic arousal becomes unmistakable. Heart rate and blood pressure rise noticeably.
Full stimulant effect — maximum alertness, cognitive euphoria, and sympathomimetic activation. Focus enhancement and thought acceleration are most pronounced. Compulsive redosing urge may emerge.
Gradual decline in stimulation. Cognitive fatigue begins to replace focus enhancement. Residual wakefulness persists while mood and motivation drop.
Residual wakefulness and possible irritability. Appetite slowly returns. Cognitive fatigue and low mood may linger.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 4 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- dopamine · stimulant
Toxicity
No lethal dose has been established for ethcathinone in any species, and no dedicated toxicology studies have been published.
Acute toxicity
The sole published case report involved a 22-year-old woman who ingested ethcathinone alongside methylone and alcohol.[6] She developed seizures, dangerous sodium depletion (Na⁺ = 120 mmol/L), and severe muscle breakdown (CK = 34,537 U/L). She survived after treatment with concentrated saline and a 6-day hospitalization. Because multiple substances were involved, the toxicity cannot be attributed to ethcathinone alone.
Cardiovascular toxicity
Ethcathinone's norepinephrine-releasing mechanism predicts dose-dependent increases in heart rate and blood pressure. For synthetic cathinones broadly, the UK ACMD documents rapid heart rate, high blood pressure, abnormal heart rhythms, chest pain, and rare cases of heart attack, stroke, and cardiac arrest.[7] No ethcathinone-specific cardiovascular data exist. inferred
Metabolic and systemic toxicity
Class-level cathinone risks include dangerously elevated body temperature, metabolic acidosis, muscle breakdown, and kidney failure.[17] The muscle breakdown in the clinical case report aligns with this class pattern.[6]
Forensic detections
Ethcathinone appears infrequently in forensic casework. Polish data (2012–2014) identified it in 5 of 112 novel psychoactive substance cases.[18] Italian postmortem hair analysis detected it alongside up to eight other cathinones in a single sample.[19] The UK ACMD recorded only 20 total detections from 2020–2023, noting it is "infrequently implicated as cause of death".[7] In 2026, ethcathinone was found in school-confiscated vapes in the UK sold as THC products.[9]
Psychological risks
No controlled data on ethcathinone's psychological risks exist. For synthetic cathinones as a class:
- Acute psychiatric effects include agitation, confusion, psychosis, paranoia, hallucinations, and delirium.[20]
- Neurological emergencies including brain swelling, coma, convulsions, and serotonin syndrome have been documented.[16]
- Chronic use can induce psychosis, hypomania, paranoid thinking, and delusions.[20]
The seizure in the clinical case report was attributed to sodium depletion rather than direct neurotoxicity,[6] but direct seizure threshold reduction at high doses — a class-level cathinone risk — cannot be excluded.
No data on persistent perceptual changes, post-acute psychiatric effects, or cognitive consequences of acute or chronic ethcathinone exposure have been published.
Tolerance and dependence
Tolerance
Synthetic cathinones develop tolerance with repeated use through transporter downregulation and receptor desensitization.[15] No ethcathinone-specific tolerance data have been published. safety citation needed
Dependence
Animal studies confirm rewarding properties for the cathinone class broadly.[21] Brain reward studies with the close structural analog 4-MEC show reward circuit activation at lower potency than methamphetamine,[22] consistent with moderate rather than high reinforcement.
Ethcathinone's norepinephrine-preferential profile with weak dopamine activity predicts lower abuse liability than dopamine-dominant cathinones, since the reinforcing properties of stimulants track primarily with dopamine release magnitude.[12]
Withdrawal
No withdrawal data exist for ethcathinone. Class-level withdrawal from synthetic cathinones is primarily psychological: fatigue, low mood, craving, and anhedonia. Physical withdrawal symptoms are generally mild or absent.
Drug interactions
Tramadol
Classified as lethal. Tramadol blocks serotonin and norepinephrine reuptake, releases serotonin, and lowers the seizure threshold. Combined with ethcathinone's norepinephrine and serotonin release, the mixture creates additive risk of serotonin syndrome, seizures, and cardiovascular collapse.[23] safety citation needed
MDMA
Classified as dangerous. Both compounds release serotonin, creating additive risk of serotonin syndrome,[24] dangerously elevated body temperature, sodium depletion,[6] and cardiovascular overload. safety citation needed
Alcohol
Classified as unknown. No published data on this combination exist. Alcohol was present in the sole clinical case report alongside ethcathinone and methylone[6] but its contribution to toxicity was not analyzed.
MAOIs
As a monoamine releaser, ethcathinone combined with monoamine oxidase inhibitors poses a risk of dangerously high blood pressure or serotonin syndrome — a class-level contraindication for all monoamine-releasing stimulants.[25] safety citation needed
Multiple substance co-ingestion
Co-ingestion of multiple novel psychoactive substances — the most common real-world pattern among cathinone users — represents the highest-risk scenario.[25] Forensic casework consistently identifies ethcathinone alongside other cathinones and conventional drugs of abuse.[18][19]
Contraindications
- Heart disease or high blood pressure (absolute): Ethcathinone's norepinephrine release directly increases heart rate, blood pressure, and cardiac workload.
- Seizure disorder (absolute): Seizures have been documented in the context of ethcathinone ingestion.[6]
- Concurrent MAOI use (absolute): Risk of dangerously high blood pressure and serotonin syndrome.
- Concurrent serotonergic drugs (relative): SSRIs, SNRIs, tramadol, and MDMA increase serotonin syndrome risk.
- Liver impairment (relative): CYP3A4 involvement in ethcathinone metabolism[14] implies impaired clearance, potentially prolonging and intensifying effects.
- Pregnancy (absolute): No reproductive data exist. Contraindicated by precautionary principle.
- History of psychosis, mania, or severe anxiety (relative): Cathinone use can trigger psychosis, hypomania, and paranoid thinking.[20]
Harm Reduction[edit]
Forms & Identification
Ethcathinone typically appears as a white crystalline powder or in capsules. It is visually indistinguishable from dozens of other cathinone powders, and even laboratory analysis faces challenges — the compound produces thermal degradation artifacts during standard gas chromatography that can complicate identification.[26] Any powder sold as ethcathinone should be treated as unverified until tested through a drug checking service.
The 2026 detection of ethcathinone in UK school-confiscated vapes marketed as THC products[9] demonstrates that this compound can appear in products not sold as cathinones at all. Testing is especially important when the source or labeling is uncertain.
Guidelines
- Test all material with a reagent kit and, where possible, a drug checking service before use.
- Start with the lowest reported active dose and wait at least 90 minutes before considering redosing — compulsive redosing is a consistently reported pattern with this compound.
- Stay hydrated but do not overdrink. The clinical case report documented dangerous sodium depletion linked in part to excessive water intake (3.5 L).[6]
- Monitor heart rate if possible. Persistent tachycardia, chest pain, or irregular heartbeat warrants stopping activity and seeking medical evaluation.
- Avoid insufflation where possible — it produces more intense effects with shorter duration and reportedly intensifies compulsive redosing.
- Eat a meal before use to support sustained energy and reduce post-experience crashes.
- Have a sober companion present, particularly at higher doses or with unfamiliar material.
Set & Setting
Ethcathinone's noradrenergic dominance produces strong physical arousal. In anxious or unfamiliar settings, the stimulation can tip toward restlessness and paranoia rather than productive energy. A calm, familiar environment with trusted company reduces the likelihood of anxiety escalation.
Avoid use when sleep-deprived or dehydrated, as both amplify cardiovascular strain. The experience is more manageable in settings where physical activity or movement is natural than in confined, sedentary environments.
Aftercare & integration. The comedown from ethcathinone is primarily characterized by fatigue, low mood, and difficulty sleeping as norepinephrine reserves recover. Prioritize sleep — use a dark, quiet room and avoid further stimulant intake including caffeine. Eat a full meal even if appetite remains suppressed; complex carbohydrates and protein support neurotransmitter recovery.
If anxiety, paranoia, or low mood persist beyond 48 hours, or if compulsive redosing occurred during the session, consider speaking with a healthcare provider or harm reduction service.
Recovery & Support
Ethcathinone's compulsive redosing pattern can escalate to habitual use. If use is becoming more frequent, doses are increasing, or cravings persist between sessions, professional support is warranted. Stimulant-specific treatment programs, cognitive behavioral therapy, and peer support groups such as SMART Recovery can help. A healthcare provider can assess whether underlying conditions are contributing to use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Chest pain, seizures, loss of consciousness, body temperature hot to the touch through clothing, confusion or agitation severe enough to prevent communication, or blue-grey discoloration of lips or fingertips.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. If body temperature is dangerously high, move to a cool area and apply cool (not ice-cold) water to skin.
- 4. Do not restrain an agitated person unless they pose immediate danger to themselves or others.
- 5. Do not induce vomiting.
What to tell the dispatcher: The substance taken (ethcathinone or synthetic cathinone), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for cathinone stimulant overdose. Treatment is supportive.
Legal Status[edit]
Ethcathinone is controlled in most major jurisdictions, typically under generic cathinone provisions rather than substance-specific scheduling. Denmark banned it as early as December 2008, making it one of the first synthetic cathinones to attract regulatory attention. The compound is not specifically named in the United States Controlled Substances Act but is likely enforceable under the Federal Analogue Act when intended for human consumption.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applicable | Enforceable as a cathinone analog when intended for human consumption. Exact federal scheduling status requires DEA confirmation. citation needed |
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Controlled under generic cathinone clause enacted in 2010; reinforced by the Psychoactive Substances Act 2016[7] |
| Germany | Anlage II BtMG (Schedule II) | Controlled since July 26, 2012. No authorized trade without license[27] |
| Denmark | Banned | Controlled since December 18, 2008 — one of the earliest national bans on a synthetic cathinone[27] |
| Poland | Group I-P controlled substance | Controlled; ethcathinone detected in forensic casework from 2012 onward[18] |
| China | Controlled substance | Controlled since October 2015[27] |
| Brazil | F2 classification | Listed under controlled substance provisions[27] |
| Australia | Controlled substance | Listed by the Office of Drug Control. Specific schedule not confirmed. citation needed |
| Canada | Likely covered under cathinone catch-all or analog provisions | No specific schedule confirmation found. citation needed |
Analog and prodrug considerations
Ethcathinone's status as the active metabolite of diethylpropion (amfepramone) — a substance with ongoing pharmaceutical licensing in several countries — creates a regulatory asymmetry. The parent prodrug is a controlled but therapeutically available medicine, while its pharmacologically active metabolite circulates as an illicit novel psychoactive substance when sold independently. This relationship has not been explicitly addressed in published regulatory analyses.
references
- [1]
- [2] ^abcShi HF, Xu BP, Xu CX, Zhou XQ, Xu HF (2023) Rapid extraction and detection of five alkaloids in dried khat by solvent extraction-HPLC-Q-TOF-MS — Se Pu (Chinese Journal of Chromatography) doi:10.3724/sp.j.1123.2023.03009
- [3] ^abcdBeckett AH, Stanojcić M (1987) Re-evaluation of the metabolism and excretion of diethylpropion in non-sustained and sustained release formulations — Journal of Pharmacy and Pharmacology PMID:2886596
- [4] ^abCamilleri A, Johnston MR, Brennan M, Davis S, Caldicott DG (2010) Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone — Forensic Science International doi:10.1016/j.forsciint.2009.12.048
- [5] ^abcNadal-Gratacós N, Pazos MD, Pubill D, Camarasa J, Escubedo E, Berzosa X, López-Arnau R (2024) Structure-Activity Relationship of Synthetic Cathinones: An Updated Review — ACS Pharmacology and Translational Science doi:10.1021/acsptsci.4c00299
- [6]